BioAge Labs Files S-1 for Public Offering

Ticker: BIOA · Form: S-1 · Filed: Sep 3, 2024 · CIK: 1709941

Bioage Labs, INC. S-1 Filing Summary
FieldDetail
CompanyBioage Labs, INC. (BIOA)
Form TypeS-1
Filed DateSep 3, 2024
Risk Levelmedium
Pages15
Reading Time18 min
Key Dollar Amounts$150 billion
Sentimentneutral

Sentiment: neutral

Topics: ipo, registration-statement, pharmaceutical

TL;DR

BioAge Labs is going public, filing its S-1 today.

AI Summary

BioAge Labs, Inc., a Delaware-based company in the pharmaceutical preparations sector, filed an S-1 registration statement on September 3, 2024. The company, located at 1445A South 50th Street, Richmond, California, is seeking to register securities for public offering. Kristen Fortney, Ph.D., serves as the Chief Executive Officer and President.

Why It Matters

This S-1 filing indicates BioAge Labs is preparing to become a publicly traded company, which could provide it with capital for research and development and increase its visibility in the pharmaceutical industry.

Risk Assessment

Risk Level: medium — As a company filing an S-1, BioAge Labs is in the process of going public, which inherently carries risks associated with market reception and the company's ability to execute its business plan.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of this S-1 filing?

The S-1 filing is a registration statement required by the SEC for companies planning to offer securities to the public.

When was the S-1 filing submitted?

The S-1 filing was submitted on September 3, 2024.

Who is the CEO of BioAge Labs, Inc.?

Kristen Fortney, Ph.D. is the Chief Executive Officer and President of BioAge Labs, Inc.

What is BioAge Labs, Inc.'s principal business address?

BioAge Labs, Inc.'s principal executive offices are located at 1445A South 50th Street, Richmond, California, 94804.

What is the SIC code for BioAge Labs, Inc.?

The Standard Industrial Classification code for BioAge Labs, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 4,464 words · 18 min read · ~15 pages · Grade level 14.2 · Accepted 2024-09-03 16:02:15

Key Financial Figures

Filing Documents

Risk Factors

Risk Factors 17 Special Note Regarding Forward Looking 77 Market and Industry Data 79

Use of Proceeds

Use of Proceeds 80 Dividend Policy 82 Capitalization 83

Managements Discussion and Analysis of Financial Condition and Results

Managements Discussion and Analysis of Financial Condition and Results of Operations 88

Business

Business 108 Management 166 Page

Executive Compensation

Executive Compensation 175 Certain Relationships and Related Party Transactions 189 Principal Stockholders 192

Description of Capital Stock

Description of Capital Stock 195 Shares Eligible for Future Sale 202 Material U.S. Federal Income Tax Consequences to Non-U.S. Holders 204

Underwriting

Underwriting 209 Legal Matters 217 Experts 217 Where You Can Find Additional Information 217 Index to Consolidated Financial Statements F-1 Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters do not take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or the time of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. Through and including , 2024 (the 25th day after the date of this prospectus), all dealers that buy, sell or trade shares of our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing